1. Search Result
Search Result
Results for "

A8343 pkc Inhibitors

" in MedChemExpress (MCE) Product Catalog:

245

Inhibitors & Agonists

2

Screening Libraries

2

Fluorescent Dye

3

Biochemical Assay Reagents

46

Peptides

52

Natural
Products

7

Recombinant Proteins

10

Isotope-Labeled Compounds

16

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1286

    PKC Neurological Disease
    PKC β pseudosubstrate is a selective cell-permeable inhibitor of PKC .
    <em>PKC</em> β pseudosubstrate
  • HY-16903

    PKC Inflammation/Immunology
    PKC-IN-1 is a potent, ATP-competitive and reversible inhibitor of conventional PKC enzymes with Kis of 5.3 and 10.4 nM for human PKCβ and PKCα, and IC50s of 2.3, 8.1, 7.6, 25.6, 57.5, 314, 808 nM for PKCα, PKCβI, PKCβII, PKCθ, PKCγ, PKC mu and PKCε, respectively.
    <em>PKC</em>-IN-1
  • HY-112681

    PKC Others
    PKC-theta inhibitor is a selective PKC-θinhibitor, with an IC50 of 12 nM.
    <em>PKC</em>-theta inhibitor
  • HY-P1286A

    PKC Neurological Disease
    PKC β pseudosubstrate TFA is a selective cell-permeable inhibitor of PKC .
    <em>PKC</em> β pseudosubstrate TFA
  • HY-P1372

    PKC Others
    PKC ζ pseudosubstrate, a PKC ζ inhibitor peptide, can be attached to cell permeabilization vector peptide .
    <em>PKC</em> ζ pseudosubstrate
  • HY-147712

    PKC Inflammation/Immunology
    PKC-IN-4 (compound 7l) is a potent and orally active aPKC inhibitor with an IC50 of 0.52 µM. PKC-IN-4 inhibits TNF-α induced NF-κB activity in vitro. PKC-IN-4 blocks VEGF- and TNFα-induced permeability across the retinal vasculature .
    <em>PKC</em>-IN-4
  • HY-P10085

    PKC Inflammation/Immunology
    PKC-ε translocation inhibitor peptide is a PKC-ε translocation inhibitor. PKC-ε translocation inhibitor peptide can regulate the rate of FcγR-mediated internalization of opsonized beads, has no effect of FcαR trafficking .
    <em>PKC</em>-ε translocation inhibitor peptide
  • HY-128142

    PKD PKC Cardiovascular Disease
    PKC/PKD-IN-1 (Compound 13C) is an orally active dual protein kinase C/D (PKC/PKD) inhibitor with an IC50 value of 0.6 nM for PKD1. PKC/PKD-IN-1 can attenuate high-salt diet-induced cardiac hypertrophy and can be used in the study of heart failure .
    <em>PKC</em>/PKD-IN-1
  • HY-P3842

    PKC Cancer
    Protein Kinase C (661-671) is a fragment peptide of β1 subspecies of protein kinase C (PKC). PKC plays a role in cellular growth control and tumor promotion .
    Protein Kinase C (661-671)
  • HY-144307

    Aurora Kinase PKC Cancer
    Aurora A/PKC-IN-1 (Compound 2e) is a potent dual inhibitor of Aurora A (AurA) and PKC (α, β1, β2, and θ) kinases with IC50s of 6.9 nM and 16.9 nM for AurA and PKCα, respectively. Aurora A/PKC-IN-1 has antiproliferative activity in breast cancer cells and antimetastatic activity .
    Aurora A/<em>PKC</em>-IN-1
  • HY-126328

    PKC Inflammation/Immunology
    PKC-theta inhibitor 1 is the PKCθ inhibitor with an Ki value of 6 nM, inhibits IL-2 production in vivo with an IC50 of 0.19 μM. PKC-theta inhibitor 1 demonstrates a reduction of symptoms in a mouse model of multiple sclerosis .
    <em>PKC</em>-theta inhibitor 1
  • HY-126146
    PKC-iota inhibitor 1
    2 Publications Verification

    PKC Cancer
    PKC-iota inhibitor 1 (compound 19) is a protein kinase C-iota (PKC-ι ℩) inhibitor with an IC50 value of 0.34 μM .
    <em>PKC</em>-iota inhibitor 1
  • HY-P3879

    pkc βII (660-673)

    PKC Others
    Protein Kinase C (660-673) (PKC βII (660-673)) is the PKC βII V5 peptide with RACK1-binding affinity .
    Protein Kinase C (660-673)
  • HY-P3770

    PKC Others
    Phosphate acceptor peptide is a substrate for cAMP-dependent protein kinase (PKA). phosphate acceptor peptide is also a weak PKC inhibitor .
    Phosphate acceptor peptide
  • HY-P1288

    pkc fragment (530-558)

    PKC Others
    Protein Kinase C (530-558), a peptide fragment of protein kinase C (PKC), is a potent PKC activator. Protein Kinase C (530-558) significantly inhibits osteoclastic bone resorption .
    Protein Kinase C (530-558)
  • HY-N11003

    PKC Others
    Vanicoside A is a protein kinase C(PKC) inhibitor from Polygonum pensylvanicum .
    Vanicoside A
  • HY-P5886

    Myristoylated protein kinase C inhibitor 20-28

    PKC Cancer
    PKC 20-28,myristoylated (Myristoylated protein kinase C inhibitor 20-28) is a cell-permeable PKC inhibitor that can be used in cancer research .
    <em>PKC</em> 20-28,myristoylated
  • HY-P5988

    PKC Cancer
    N-myristoyl-RKRTLRRL inhibits binding of PKC substrates. N-myristoyl-RKRTLRRL inhibits Ca 2+- and phosphatidylserine (PS)-dependent histone phosphorylation with IC50 of 5 μM.? histone phosphorylation with IC50 of 80 μM .
    N-myristoyl-RKRTLRRL
  • HY-101195

    PKC Phospholipase Cancer
    DL-erythro-Dihydrosphingosine is a potent inhibitor of PKC and phospholipase A2 (PLA2) .
    DL-erythro-Dihydrosphingosine
  • HY-107421

    PKC HIV Infection Cancer
    Prostratin, a natural terpenoid compound, is a PKC activator, with a Ki of 12.5 nM and shows inhibitory effect on HIV-1.
    Prostratin
  • HY-10230
    Midostaurin
    20+ Cited Publications

    pkc412; CGP 41251

    PKC VEGFR c-Kit NO Synthase Apoptosis Cancer
    Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .
    Midostaurin
  • HY-P3940

    PKC Others
    Ac-MBP (4-14) Peptide is an acetylated MBP (4-14) peptide. MBP (4-14) Peptide is a very selective (protein kinase C) PKC substrate. Ac-MBP (4-14) Peptide can be used for PKC assay in extracts without prior purification to eliminate interfering protein kinases or phosphatases .
    Ac-MBP (4-14) Peptide
  • HY-P1289A

    PKC Others
    [Ala107]MBP(104-118) is an noncompetitive peptide inhibitors of protein kinase C (PKC), with IC50s ranging from 46-145 μM .
    [Ala107]MBP(104-118)
  • HY-P1289

    PKC Others
    [Ala113]MBP(104-118) is an noncompetitive peptide inhibitors of protein kinase C (PKC), with IC50s ranging from 28-62 μM .
    [Ala113]MBP(104-118)
  • HY-P1746

    pkc (19-31)

    PKC Inflammation/Immunology
    Protein Kinase C (19-31), a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31), is used as protein kinase C substrate peptide for testing the protein kinase C activity .
    Protein Kinase C (19-31)
  • HY-P1289C

    PKC Others
    [Ala113]MBP(104-118) TFA is an noncompetitive peptide inhibitors of protein kinase C (PKC), with IC50s ranging from 28-62 μM .
    [Ala113]MBP(104-118) TFA
  • HY-P1289B

    PKC Others
    [Ala107]MBP(104-118) TFA is an noncompetitive peptide inhibitors of protein kinase C (PKC), with IC50s ranging from 46-145 μM .
    [Ala107]MBP(104-118) TFA
  • HY-129491S

    CGP62221-d5; O-Desmethyl pkc412-d5

    Isotope-Labeled Compounds Drug Metabolite Cancer
    O-Desmethyl Midostaurin-d5 is a deuterium labeled O-Desmethyl PKC412. O-Desmethyl Midostaurin (CGP62221; O-Desmethyl PKC412) is the active metabolite of Midostaurin (HY-10230) via cytochrome P450 liver enzyme metabolism[1].
    O-Desmethyl Midostaurin-d5
  • HY-P1746A

    pkc (19-31) (TFA)

    PKC Inflammation/Immunology
    Protein Kinase C (19-31) TFA, a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31), is used as protein kinase C substrate peptide for testing the protein kinase C activity .
    Protein Kinase C (19-31) (TFA)
  • HY-120515

    PKC Cancer
    7-Oxostaurosporine is a potent protein kinase C (PKC) inhibitor that effectively inhibits tumor growth by inducing apoptosis and inhibiting the nuclear factor (NF)-κB/p-p65 pathway .
    7-Oxostaurosporine
  • HY-110013

    Btk Antibiotic Infection Inflammation/Immunology
    Terreic acid, a quinone epoxide antibiotic, acts as an effective Btk inhibitor. Terreic acid blocks the interaction between PKC and the pleckstrin homology domain of Btk. Terreic acid inhibits the binding of GST-BtkPH to PKC in lysates of HMC-1 human mast cells with an IC50 of approximately 100 μM .
    Terreic acid
  • HY-129491

    CGP62221; O-Desmethyl pkc412

    PKC Cancer
    O-Desmethyl Midostaurin (CGP62221; O-Desmethyl PKC412) is the active metabolite of Midostaurin (HY-10230) via cytochrome P450 liver enzyme metabolism. O-Desmethyl Midostaurin can be used as an indicator for Midostaurin metabolism in vivo . Midostaurin is a multi-targeted protein kinase inhibitor with IC50 ranging from 22-500 nM.
    O-Desmethyl Midostaurin
  • HY-P4987

    Protease Activated Receptor (PAR) Cardiovascular Disease
    TRAP-7 is a thrombin receptor (PAR) activating peptide. TRAP-7 stimulates total inositol phosphate (IP) accumulation and phosphorylation of a specific endogenous substrate for activated PKC. TRAP-7 can be used in cardiovascular disease research .
    TRAP-7
  • HY-115767

    1,2-Dioleoyl-rac-glycerol

    PKC Others
    (±)-1,2-Diolein (1,2-Dioleoyl-rac-glycerol) is a PKC activator. (±)-1,2-Diolein increases myotubes Ca 2+ influx .
    (±)-1,2-Diolein
  • HY-112412

    PDGF Receptor Tyrosine Kinase Inhibitor III

    PDGFR Neurological Disease
    PDGFR Tyrosine Kinase Inhibitor III (PDGF Receptor Tyrosine Kinase Inhibitor III), a multikinase inhibitor, inhibits PDGFR, EGFR, FGFR, PKA, and PKC, respectively. PDGFR Tyrosine Kinase Inhibitor III can be used for the research of amyotrophic lateral sclerosis .
    PDGFR Tyrosine Kinase Inhibitor III
  • HY-118442

    Tetradecasphing-4-enine

    PKC Cancer
    Sphingosine (d14:1) (Tetradecasphing-4-enine), a sphingolipid, is a potent Protein kinase C (PKC) inhibitor. Sphingosine (d14:1) prevents its interaction with sn-1,2-diacylglycerol (DAG)/Phorbol esters .
    Sphingosine (d14:1)
  • HY-10230S

    pkc412-d5; CGP 41251-d5

    Isotope-Labeled Compounds PKC Syk Akt PKA c-Kit Cancer
    Midostaurin-d5 is a deuterium labeled Midostaurin. Midostaurin is a multi-targeted protein kinase inhibitor which inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM[1].
    Midostaurin-d5
  • HY-131897
    1-Stearoyl-2-arachidonoyl-sn-glycerol
    1 Publications Verification

    PKC TRP Channel Endogenous Metabolite Neurological Disease
    1-Stearoyl-2-arachidonoyl-sn-glycerol is a diacylglycerol (DAG) containing polyunsaturated fatty acids. 1-Stearoyl-2-arachidonoyl-sn-glycerol can activate PKC. 1-Stearoyl-2-arachidonoyl-sn-glycerol also can augment nonselective cation channel (NSCC) activity .
    1-Stearoyl-2-arachidonoyl-sn-glycerol
  • HY-13689
    Go 6983
    45+ Cited Publications

    Gö 6983; Goe 6983

    PKC Cancer
    Go 6983 is a pan-PKC inhibitor against for PKCα, PKCβ, PKCγ, PKCδ and PKCζ with IC50 of 7 nM, 7 nM, 6 nM, 10 nM and 60 nM, respectively.
    Go 6983
  • HY-13335

    PKC Apoptosis Cancer
    PKCβ inhibitor 1 is a potent, ATP-competitive, and selective PKCβ inhibitor with IC50s of 21 and 5 nM for human PKCβ1 and PKCβ2, respectively. PKCβ inhibitor 1 exhibits selectivity of more than 60-fold in favor of PKCβ2 relative to other PKC isozymes (PKCα, PKCγ, and PKCε) .
    PKCβ inhibitor 1
  • HY-10343
    Sotrastaurin
    15+ Cited Publications

    AEB071

    PKC Inflammation/Immunology Cancer
    Sotrastaurin (AEB071) is a potent and orally-active pan-PKC inhibitor, with Kis of 0.22 nM, 0.64 nM, 0.95 nM, 1.8 nM, 2.1 nM and 3.2 nM for PKCθ, PKCβ, PKCα, PKCη, PKCδ and PKCε, respectively .
    Sotrastaurin
  • HY-117610A
    Bisindolylmaleimide XI hydrochloride
    2 Publications Verification

    Ro 32-0432; Ro 31-8830 hydrochloride

    PKC Inflammation/Immunology
    Bisindolylmaleimide XI hydrochloride (Ro 32-0432) is a potent, selective and orally active PKC inhibitor with IC50s of 9 nM, 28 nM, 31 nM, 37 nM, and 108 nM for PKCα, PKCβI, PKCβII, PKCγ, and PKCε, respectively .
    Bisindolylmaleimide XI hydrochloride
  • HY-131305

    PKC Apoptosis Neurological Disease
    HBDDE, a derivative of Ellagic acid, is an isoform-selective PKCα and PKCγ inhibitor with IC50s of 43 μM and 50 μM, respectively. HBDDE shows selective for PKCα/PKCγ over PKCδ, PKCβI and PKCβII isozymes. HBDDE induces neuronal apoptosis .
    HBDDE
  • HY-139466

    SHP2 PKC Metabolic Disease
    PF-03622905 is a potent and ATP-competitive PKC inhibitor with IC50s of 5.6 nM, 14.5 nM, 13 nM, 37.7 nM, and 74.1 nM for PKCα, PKCβI, PKCβII, PKCγ, and PKCθ, respectively. PF-03622905 shows high specificity for PKC over other protein kinases .
    PF-03622905
  • HY-112291

    p38 MAPK Src PKC Inflammation/Immunology
    SB 220025 is a reversible, orally active, cell-permeable, ATP-competitive and selective human p38 MAPK inhibitor (IC50 = 60 nM). SB 220025 also inhibits p56 Lck and PKC with IC50 values of 3.5 and 2.89 µM, respectively. SB 220025 inhibits the expression of IL-8 gene in response to globular adiponectin (gAd), reduces inflammatory cytokine production and inhibits angiogenesis. SB 220025 effectively prevents the progression of arthritis in a chronic inflammatory disease model and can be used in the study of inflammation .
    SB 220025
  • HY-B0719
    Ingenol Mebutate
    1 Publications Verification

    Ingenol 3-angelate; PEP005

    PKC Inflammation/Immunology Cancer
    Ingenol Mebutate is an active ingredient in Euphorbia peplus, acts as a potent PKC modulator, with Kis of 0.3, 0.105, 0.162, 0.376, and 0.171 nM for PKC-α, PKC-β, PKC-γ, PKC-δ, and PKC-ε, respectively, and has antiinflammatory and antitumor activity.
    Ingenol Mebutate
  • HY-13867
    Bisindolylmaleimide I
    30+ Cited Publications

    GF109203X; Go 6850

    PKC GSK-3 Metabolic Disease Cancer
    Bisindolylmaleimide I (GF109203X) is a cell-permeable and reversible PKC inhibitor (IC50 of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ. Bisindolylmaleimide I is also a GSK-3 inhibitor .
    Bisindolylmaleimide I
  • HY-13867A

    GF109203X hydrochloride; Go 6850 hydrochloride

    PKC GSK-3 Metabolic Disease Cancer
    Bisindolylmaleimide I (GF109203X) hydrochloride is a cell-permeable and reversible PKC inhibitor (IC50 of 20 nM, 17 nM, 16 nM, and 20 nM for PKCα, PKCβI, PKCβII, and PKCγ. Bisindolylmaleimide I hydrochloride is also a GSK-3 inhibitor .
    Bisindolylmaleimide I hydrochloride
  • HY-10342
    Enzastaurin
    5+ Cited Publications

    LY317615

    PKC Autophagy Apoptosis Cancer
    Enzastaurin (LY317615) is a potent and selective PKCβ inhibitor with an IC50 of 6 nM, showing 6- to 20-fold selectivity over PKCα, PKCγ and PKCε .
    Enzastaurin
  • HY-129624A

    Ro 31-7549 acetate; Bis VIII acetate

    PKC Apoptosis Inflammation/Immunology Cancer
    Bisindolylmaleimide VIII acetate (Ro 31-7549 acetate) is a potent and selective protein kinase C (PKC) inhibitor with an IC50 of 158 nM for rat brain PKC. Bisindolylmaleimide VIII acetate has IC50s of 53, 195, 163, 213, and 175 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, PKC-ε, respectively . Bisindolylmaleimide VIII acetate facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases .
    Bisindolylmaleimide VIII acetate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: